Evotec Stock: Sharp Decline Continues Amid Investor Changes

Evotec SE shares slumped 4.2% to €6.32 on XETRA trading, touching a daily low of €6.30 after opening at €6.72. With trading volume reaching 763,197 shares, the biotech company's stock continues its troubling trajectory, now sitting 57.2% below its 52-week high of €14.77 reached in March 2024. While current prices remain 24.9% above the August low of €5.06, the overall trend remains decidedly negative. The Hamburg-based firm's financial performance offers little comfort, with recent quarterly results showing a loss of €0.22 per share and a 5.8% revenue decline to €184.89 million compared to the same period last year. Analysts maintain pessimistic forecasts, projecting a €0.762 per share loss for the full year 2024 with an average price target of €9.68.

Institutional Investors Adjust Positions

Sollten Anleger sofort verkaufen? Oder lohnt sich doch der Einstieg bei Evotec?

Notable shifts in Evotec's shareholder base may be contributing to market volatility. American asset manager T. Rowe Price Group recently modified its stake, now holding 3.09% of voting rights directly plus 1.77% through financial instruments, totaling 4.86%. Meanwhile, Canadian investment firm Connor, Clark & Lunn Financial Group reduced its position from 3.06% to 2.89%, falling below the 3% reporting threshold. These ownership changes reflect ongoing uncertainty surrounding the company's prospects as it struggles to reverse its financial and market performance decline.

Ad

Evotec Stock: New Analysis - 11 March

Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Evotec analysis...